GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pharmaron Beijing Co Ltd (HKSE:03759) » Definitions » Cash Flow for Dividends

Pharmaron Beijing Co (HKSE:03759) Cash Flow for Dividends : HK$-595 Mil (TTM As of Sep. 2024)


View and export this data going back to 2019. Start your Free Trial

What is Pharmaron Beijing Co Cash Flow for Dividends?

Pharmaron Beijing Co's cash flow for dividends for the three months ended in Sep. 2024 was HK$-121 Mil. Its cash flow for dividends for the trailing twelve months (TTM) ended in Sep. 2024 was HK$-595 Mil.

Note: A negative number here means the payment of dividends. When pays more dividends, the absolute value gets bigger.

Pharmaron Beijing Co's quarterly payment of dividends increased from Mar. 2024 (HK$-50 Mil) to Jun. 2024 (HK$-369 Mil) but then declined from Jun. 2024 (HK$-369 Mil) to Sep. 2024 (HK$-121 Mil).

Pharmaron Beijing Co's annual payment of dividends increased from Dec. 2021 (HK$-349 Mil) to Dec. 2022 (HK$-452 Mil) and increased from Dec. 2022 (HK$-452 Mil) to Dec. 2023 (HK$-487 Mil).

Pharmaron Beijing Co Cash Flow for Dividends Historical Data

The historical data trend for Pharmaron Beijing Co's Cash Flow for Dividends can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pharmaron Beijing Co Cash Flow for Dividends Chart

Pharmaron Beijing Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash Flow for Dividends
Get a 7-Day Free Trial Premium Member Only Premium Member Only -159.34 -160.51 -348.62 -452.00 -486.50

Pharmaron Beijing Co Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Cash Flow for Dividends Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -394.86 -54.33 -50.30 -369.47 -120.71

Pharmaron Beijing Co Cash Flow for Dividends Calculation

Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.

Cash Flow for Dividends for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was HK$-595 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pharmaron Beijing Co Cash Flow for Dividends Related Terms

Thank you for viewing the detailed overview of Pharmaron Beijing Co's Cash Flow for Dividends provided by GuruFocus.com. Please click on the following links to see related term pages.

Pharmaron Beijing Co Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pharmaron Beijing Co Ltd (HKSE:03759) » Definitions » Cash Flow for Dividends
Comparable Companies
SZSE:002821 SHSE:603392 SHSE:600161 SZSE:002252 SZSE:002007 SZSE:002653 SHSE:603233 SHSE:688520 SZSE:301301 SHSE:688278 OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
17Q1:Germany 300759:China
Address
No. 248 Queen’s Road East, 40th Floor, Dah Sing Financial Centre, Wanchai, Hong Kong, HKG
Website
https://www.pharmaron.com
Pharmaron Beijing Co Ltd is a research and development service company supporting the life science industry. The company offers drug research and development service capabilities, ranging from synthetic, medicinal, and analytical chemistry, biology, DMPK, pharmacology, drug safety assessment, radiochemistry and isotopically labelled metabolism, chemical and pharmaceutical development to clinical development. The company's operating segment includes Laboratory services; CMC (small molecule CDMO) services; Clinical development services and biologics and CGT services. It generates maximum revenue from the Laboratory services segment.
Executives
Morgan Stanley 2201 Interest of corporation controlled by you
Jpmorgan Chase & Co. 2201 Interest of corporation controlled by you
The Bank Of New York Mellon Corporation 2201 Interest of corporation controlled by you
Citigroup Inc. 2201 Interest of corporation controlled by you
Blackrock, Inc. 2201 Interest of corporation controlled by you
Gic Private Limited 2102 Investment manager
The Capital Group Companies, Inc. 2201 Interest of corporation controlled by you
Matthews International Capital Management, Llc 2102 Investment manager
First H Share Award And Scheme Of Pharmaron Beijing Co., Ltd. 2301 Trustee
Kastle Limited 2301 Trustee
Jian Xin Bei Jing Tou Zi Ji Jin Guan Li You Xian Ze Ren Gong Si 2201 Interest of corporation controlled by you
Jian Xin Xin Tuo You Xian Ze Ren Gong Si 2201 Interest of corporation controlled by you

Pharmaron Beijing Co Headlines

No Headlines